Skip to main content
. Author manuscript; available in PMC: 2020 Oct 17.
Published in final edited form as: Lancet Neurol. 2011 Aug 3;10(9):806–818. doi: 10.1016/S1474-4422(11)70155-7

Figure 1: FGF-21 concentrations in serum in patients with mitochondrial disorders and healthy controls.

Figure 1:

Data for patients with mitochondrial disorders are separated shown by specific disease groups. (A) Adult patients. (B) Paediatric patients. (C) FGF-21 messenger RNA expression in the skeletal muscle of six controls, two patients with MELAS, and three patients with MIRAS measured by quantitative PCR relative to β-actin. (D) Correlation between FGF-21 concentrations in serum and proportion of COX-negative fibres (n=28). Mann-Whitney U test was used to compare FGF-21 concentrations between subgroups of patients and between patients and controls, and data in A, B, and C are mean (SD) and range, and p values are for comparisons with controls. MELAS=mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. mt=mitochondrial. MIRAS=mitochondrial recessive ataxia syndrome. MNGIE=mitochondrial neurogastrointestinal encephalomyopathy. Alpers=Alpers’ encephalopathy. RC=respiratory chain. LCHAD=long-chain 3 hydroxyacyl CoA dehydrogenase deficiency. COX= cytochrome-c oxidase. *p<0·001. †p<0·01. ‡p<0·05.